These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 31746939)

  • 1. Familial hypercholesterolaemia and its management in South Africa.
    Marais AD
    Cardiovasc J Afr; 2019; 30(5):247-248. PubMed ID: 31746939
    [No Abstract]   [Full Text] [Related]  

  • 2. Familial hypercholesterolaemia in South Africa: A reminder.
    Marais AD; Blom DJ; Raal FJ; The Lipid And Atherosclerosis Society Of Southern Africa OBOTLA
    S Afr Med J; 2021 Aug; 111(8):700-701. PubMed ID: 35227347
    [No Abstract]   [Full Text] [Related]  

  • 3. Familial hypercholesterolaemia and coronary disease in South Africa.
    Pedoe HT
    Br Med J; 1980 Sep; 281(6244):872. PubMed ID: 7427490
    [No Abstract]   [Full Text] [Related]  

  • 4. Defective LDL receptors that are common in a large population. Familial hypercholesterolaemia in South Africa.
    Gevers W; Casciola LA; Fourie AM; Sanan DA; Coetzee GA; van der Westhuyzen DR
    Biol Chem Hoppe Seyler; 1987 Oct; 368(10):1233-43. PubMed ID: 3322320
    [No Abstract]   [Full Text] [Related]  

  • 5. Familial hypercholesterolaemia in South Africans: tracking findings and developments over time - with reference to : prevalence of hypercholesterolaemia in young Afrikaners with myocardial infarction. Ischaemic heart disease risk factors.
    Delport R
    Cardiovasc J Afr; 2009; 20(1):18-22. PubMed ID: 19287810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety and efficacy of alirocumab in South African patients with heterozygous familial hypercholesterolaemia: the ODYSSEY Open-Label Extension study.
    Blom DJ; Breedt J; Burgess LJ; Ebrahim IO; Ellis G; Soma P; van der Walt E; Naidoo P; van Tonder A; Raal FJ
    Cardiovasc J Afr; 2019 Sep/Oct 23; 30(5):279-284. PubMed ID: 31512717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic review of published Phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia.
    Gouni-Berthold I; Descamps OS; Fraass U; Hartfield E; Allcott K; Dent R; März W
    Br J Clin Pharmacol; 2016 Dec; 82(6):1412-1443. PubMed ID: 27478094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovering familial hypercholesterolaemia.
    Blom DJ; Raal FJ; Marais AD
    S Afr Med J; 2008 Apr; 98(4):232. PubMed ID: 18642461
    [No Abstract]   [Full Text] [Related]  

  • 9. Monogenic primary hypercholesterolaemia in South Africa.
    Rubinsztein DC; van der Westhuyzen DR; Coetzee GA
    S Afr Med J; 1994 Jun; 84(6):339-44. PubMed ID: 7740380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterozygous familial hypercholesterolaemia in specialist centres in South Africa, Australia and Brazil: Importance of early detection and lifestyle advice.
    Pang J; David Marais A; Blom DJ; Brice BC; Silva PR; Jannes CE; Pereira AC; Hooper AJ; Ray KK; Santos RD; Watts GF
    Atherosclerosis; 2018 Oct; 277():470-476. PubMed ID: 30270087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary familial hypercholesterolaemia in a South African black. A case report.
    van Wingerden JJ
    S Afr Med J; 1981 Oct; 60(14):554-6. PubMed ID: 7280910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Familial hypercholesterolaemia and church affiliation.
    Torrington M; Botha JL
    Lancet; 1981 Nov; 2(8255):1120. PubMed ID: 6118572
    [No Abstract]   [Full Text] [Related]  

  • 13. HLA antigens in South African Afrikaners with heterozygous familial hypercholesterolaemia.
    Baker SG; Rabson A; Shires R; Joffe BI; Seftel HC
    J Med Genet; 1985 Aug; 22(4):320-1. PubMed ID: 4045967
    [No Abstract]   [Full Text] [Related]  

  • 14. PCSK9: from molecular biology to clinical applications.
    Malo J; Parajuli A; Walker SW
    Ann Clin Biochem; 2020 Jan; 57(1):7-25. PubMed ID: 31257903
    [No Abstract]   [Full Text] [Related]  

  • 15. Initiation of PCSK9 inhibition in patients with heterozygous familial hypercholesterolaemia entering adulthood: a new design for living with a high-risk condition?
    Vuorio A; Watts GF; Kovanen PT
    Eur Heart J; 2016 May; 37(17):1353-6. PubMed ID: 26851704
    [No Abstract]   [Full Text] [Related]  

  • 16. Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC).
    EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)
    Lancet; 2021 Nov; 398(10312):1713-1725. PubMed ID: 34506743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Familial hypercholesterolemia in South Africa.
    Marais AD; Firth JC; Blom DJ
    Semin Vasc Med; 2004 Feb; 4(1):93-5. PubMed ID: 15199438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom.
    France M; Rees A; Datta D; Thompson G; Capps N; Ferns G; Ramaswami U; Seed M; Neely D; Cramb R; Shoulders C; Barbir M; Pottle A; Eatough R; Martin S; Bayly G; Simpson B; Halcox J; Edwards R; Main L; Payne J; Soran H;
    Atherosclerosis; 2016 Dec; 255():128-139. PubMed ID: 27839699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolocumab in Children with Heterozygous Familial Hypercholesterolemia.
    de Ferranti SD
    N Engl J Med; 2020 Oct; 383(14):1385-1386. PubMed ID: 32997915
    [No Abstract]   [Full Text] [Related]  

  • 20. Aggressive Treatment for Severe Forms of Familial Hypercholesterolemia.
    Duell PB; Fazio S
    J Am Coll Cardiol; 2020 Feb; 75(6):575-577. PubMed ID: 32057370
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.